XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets    
Investments, at fair value: $ 1,870,837 [1] $ 1,954,270 [2]
Cash 48,482 8,415
Interest receivable on investments 36,366 36,724
Receivable due on investments sold and repaid 11,452 967
Prepaid expenses and other assets 1,137 1,348
Total assets 1,968,274 2,001,724
Liabilities    
Financing arrangements (net of unamortized debt issuance costs of $9,388 and $10,643, respectively) 1,060,455 1,081,701
Payable for investments purchased 21,041 4,692
Accounts payable and accrued expenses 743 1,036
Interest payable 8,556 10,231
Accrued management fees 6,864 6,893
Accrued subordinated incentive fee on income 6,914 4,615
Accrued administrative services expense 642 2,156
Shareholder distribution payable 0 10,837
Total liabilities 1,105,215 1,122,161
Commitments and contingencies (Note 4 and Note 11)
Shareholders' Equity    
Common stock, $0.001 par value; 500,000,000 shares authorized; 53,760,605 and $54,184,636 shares issued and $$53,760,605 and $54,184,636 shares outstanding, respectively 54 54
Capital in excess of par value 1,028,360 1,033,030
Accumulated distributable losses (165,355) (153,521)
Total shareholders' equity 863,059 879,563
Total liabilities and shareholders' equity $ 1,968,274 $ 2,001,724
Net asset value per share of common stock at end of period (in dollars per share) $ 16.05 $ 16.23
Non-controlled, non-affiliated investments    
Assets    
Investments, at fair value: $ 1,494,478 $ 1,570,676
Non-controlled, affiliated investments    
Assets    
Investments, at fair value: 202,915 206,301
Controlled investments    
Assets    
Investments, at fair value: $ 173,444 $ 177,293
[1] Fair value determined in good faith by the Company’s board of directors (see Note 9), including via delegation to CIM as the Company’s valuation designee (see Note 2), using significant unobservable inputs unless otherwise noted.
[2] Fair value determined in good faith by the Company’s board of directors (see Note 9), including via delegation to CIM as the Company’s valuation designee (see Note 2), using significant unobservable inputs unless otherwise noted.